Abstract
BACKGROUND: RNA modifications are widely detected in cells and are involved in RNA structural stabilization and regulation of gene expression. In cancer cells, RNA modifications are altered, resulting in abnormal expression of numerous genes and promoting cancer growth. N1-methyladenosine (m(1)A), N6-methyladenosine (m(6)A), N3-methylcytosine (m(3)C), 5-methylcytosine (m(5)C), 7-methylguanosine (m(7)G), and N4-acetylcytidine (ac(4)C) have been reported as RNA modifications affecting gene expression. AIM: In this review, the function of m(6)A in pancreatic cancer is mainly described, and the current status and prospects of RNA modifications are discussed. METHODOLOGY: We summarize recent reports on m(6)A writers METTL3, METTL5, METTL14, and METTL16; m(6)A readers IGF2BP1, IGF2BP2, IGF2BP3, YTHDF1, YTHDF2, and YTHDF3; and m(6)A erasers ALKBH5 and FTO. RESULTS: RNA modifications are written to the RNA by the writer, and the reader binds to the RNA modification, causing gene expression to increase or decrease. Gene expression is also regulated by the removal of RNA modifications by the eraser. Moreover, our recent investigation into m(6)A modifications in pancreatic cancer has led to the identification of several promising candidate biomarkers, highlighting the potential role of epitranscriptomic regulation in tumorigenesis. CONCLUSION: These findings suggest that further exploration of RNA modification functions may facilitate the identification of novel biomarker and therapeutic target molecules for pancreatic cancer.